Johnson & Johnson beats Q2 estimates, raises full-year 2026 guidance

Johnson & Johnson beats Q2 estimates, raises full-year 2026 guidance Proactive Wed, July 15, 2026 at 4:42 PM GMT+2 2 min read JNJ Johnson & Johnson (NYSE:JNJ) reported better-than-expected second quarter results and raised its full-year 2026 outlook, as strong pharmaceutical sales helped offset headwinds from products facing patent competition. The healthcare company posted adjusted earnings per share of $2. 90 for the quarter, ahead of the Wall Street consensus estimate of $2.

85. Revenue rose 6. 6% year over year to $25.

31 billion, exceeding analysts' expectations of $25. 05 billion. Net earnings were $5.

53 billion, or $2. 27 per diluted share, compared with $5. 54 billion, or $2.

29 per share, a year earlier. Adjusted net earnings increased 5. 7% to $7.

08 billion. The Innovative Medicine segment remained the primary growth driver, with sales rising 7. 8% to $16.

38 billion, above expectations of approximately $16. 1 billion. MedTech sales increased 4.

5% to $8. 93 billion. Among individual products, immunology drug Tremfya generated $2 billion in sales, up 72.

5% from a year earlier and above analyst estimates of $1. 74 billion. Cancer therapy Darzalex also contributed to growth, helping offset the impact of patent expirations affecting older medicines such as Stelara.

Following the stronger-than-expected quarter, Johnson & Johnson (NYSE:JNJ) increased its full-year 2026 guidance. The company now expects reported sales of $100. 8 billion to $101.

4 billion, with a midpoint of $101. 1 billion, and adjusted earnings per share of $11. 60 to $11.

75, compared with its previous outlook. The updated adjusted EPS guidance has a midpoint of $11. 68.

Johnson & Johnson also reported year-to-date free cash flow of approximately $8. 7 billion, up from $6. 21 billion in the prior-year period.

Joaquin Duato, Johnson & Johnson's CEO, highlighted the company's innovation pipeline, noting recent approvals for Tremfya in active psoriatic arthritis, Caplyta for preventing relapse in schizophrenia, and the Dual Energy ThermoCool SmartTouch SF platform, alongside positive clinical data for several oncology and surgical programs. "With raised guidance and quarterly sales surpassing $25 billion, we are on track to meet our 2026 target of more than $100 billion in annual revenue for the first time in our Company's 140-year history," Duato said. Shares of Johnson & Johnson were little changed at $253 following the release of its earnings.